1,4-Butanediol Dimethanesulphonate (Myleran) (IARC Summary & Evaluation, Volume 4, 1974)

International Agency for Research on Cancer (IARC) - Summaries & Evaluations

1,4-BUTANEDIOL DIMETHANESULFONATE (MYLERAN)

VOL.: 4 (1974) (p. 247)

5. Summary of Data Reported and Evaluation

5.1 Animal carcinogenicity data

Administration of 1,4-butanediol dimethanesulfonate (Myleran) to the mouse by intraperitoneal injection and to the rat by oral administration did not significantly increase the incidence of tumours. Intravenous administration in the mouse significantly increased the incidence of thymic lymphomas and ovarian tumours. Myleran in conjunction with X-rays further augmented the incidence of thymic lymphomas. The increased incidences of thymic lymphomas and ovarian tumours are difficult to assess with respect to the carcinogenicity of Myleran in the mouse.

5.2 Human carcinogenicity data

Although there is evidence that histological and cytological changes are associated with Myleran therapy, there is no firm evidence of an increased cancer risk among those treated.

Subsequent evaluation: Suppl. 7 (1987)

Last updated: 17 March 1998





























    See Also:
       Toxicological Abbreviations
       Butanediol Dimethanesulphonate, 1,4- (Myleran)  (IARC Summary & Evaluation, Supplement7, 1987)